Evaluation of the coagulation and inflammatory responses in solid organ transplant recipients and donors

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 943-950

  Levitsky, Josh ^a   Freifeld, Alison ^b   Lyden, Elizabeth ^b   Stoner, Julie ^b   Florescu, Diana ^b   Langnas, Alan ^b   Brian Stevens, R ^b   Hardiman, Penny ^b   Hill, Lisa ^b   Kalil, Andre C ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cascades; Coagulation; Complications; Infection; Inflammation; Solid organ transplantation

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; D DIMER; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN C; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ARTICLE; BACTEREMIA; BLOOD CLOTTING; CADAVER DONOR; COLITIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PERITONITIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOSIS; TREATMENT RESPONSE; WOUND INFECTION; BLOOD; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PILOT STUDY; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INFLAMMATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN C;

EID: 71149100651     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01038.x     Document Type: Article

References (41)

1. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001, 16:83.
2. Adrie C, Pinsky MR. The inflammatory balance in human sepsis. Int Care Med 2000, 26:364.
3. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101:3765.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138.
5. Eichacker PQ, Parent C, Kalil A. Risk and the efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002, 166:1197.
6. Rubin R. The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis 2002, 22:125.
7. Humblot S, Martin T, Pasquali JP. Blood coagulation disorders during primary cytomegalovirus infection. Arch Intern Med 2001, 161:2149.
8. van Dam-Mieras MCE, Muller AD, van Hinsbergh VWN. The procoagulant response of cytomegalovirus infected cells. Thromb Haemost 1992, 62:364.
9. Bruggeman CA, Debie WHM, Muller AD. Cytomegalovirus alters the von Willebrand factor content in human endothelial cells. Thromb Haemost 1987, 59:264.
10. Woodroffe SB, Kuan S. Human cytomegalovirus infection induces mRNA expression and secretion of plasminogen inhibitor type-1 in endothelial cells. J Med Virol 1998, 55:268.
11. Sutherland MR, Raynor CM, Leenknegt H. Coagulation initiated on herpesvirus. Proc Natl Acad Sci USA 1997, 94:13510.
12. Cebulla CM, Miller DM, Knight DA. Cytomegalovirus induces sialys lewis and lewis on human endothelial cells. Transplantation 2000, 69:1202.
13. Sedmak DD, Knight DA, Vook NC. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation 1994, 58:1379.
14. Span AH, vanDam-Mieras MC, Mullers W. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells. Clin Invest 1991, 21:331.
15. Persoons MJ, Stals FS, van Dam-Mieras MC. Multiple organ involvement during experimental cytomegalovirus infection is associated with disseminated vascular pathology. J Pathol 1998, 184:103.
16. Muldoon J, O'Riordan K, Rao S. Ischemic colitis secondary to venous thrombosis. Transplantation 1996, 61:1651.
17. Ofotokum I, Carlson C, Gitlion SD. Acute cytomegalovirus infection complicated by vascular thrombosis: a case report. Clin Infect Dis 2001, 32:983.
18. Foucar E, Mukai K, Foucar K. Colon ulceration in lethal cytomegalovirus infection. Am J Clin Pathol 1981, 76:788.
19. Lee JYY. Cytomegalovirus infection involving the skin in immunocompromised hosts. A clinicopathologic study. Am J Pathol 1989, 92:96.
20. Neau D, Bonnet F, Viallard JF. Thrombotic thrombocytopenic purpura and cytomegalovirus infection in an immunocompetent adult. Clin Infect Dis 1997, 25:1495.
21. Caton B, de Otazu RD, Aldamiz-Echebarria M. Haemolytic-uraemic syndrome with thrombotic microangiopathy of the retina following cytomegalovirus infection: postmortem findings. Postgrad Med J 1993, 69:653.
22. Jejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998, 65:1645.
23. Basista MH, Stieffenhofer A, Kim DG. Procoagulant activity and tumor necrosis factor in rat hepatic allograft rejection. Hepatology 1991, 14:883.
24. Scholz T, Gallimore MJ, Bäckman L. Plasma proteolytic activity in liver transplant rejection. Transpl Int 1999, 12:100.
25. Schuurman HJ, Cheng J, Lam T. Pathology of xenograft rejection: a commentary. Xenotransplantation 2003, 10:293.
26. Chiurchiu C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy in renal transplantation. Ann Transplant 2002, 7:28.
27. Bell H, Odegaard OR, Andresson T. Protein C in patients with alcoholic cirrhosis and other liver diseases. J Hepatol 1992, 14:163.
28. Sorensen PJ, Knudsen F, Nielsen AH. Protein C activity in renal disease. Thromb Res 1985, 38:243.
29. Harenberg J, Stiehl A, Kommerell B. Protein C in patients with liver disease: indicator for liver cell dysfunction rather than for thrombotic tendency. Thromb Haemost 1985, 54:144.
30. Vaziri ND, Gonzales EC, Wang J. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994, 23:828.
31. Nguyen P, Toupance O, Chanard J. Variations of protein C in uremic hemodialysed patients. Thromb Haemost 1993, 69:509.
32. Ilmakunnas M, Petaja J, Hockerstedt K. Activation of protein C during reperfusion in clinical liver transplantation. Transplantation 2003, 75:467.
33. Deira J, Alberca I, Lerma JL. Changes in coagulation and fibrinolysis in the postoperative period immediately after kidney transplantation in patients receiving OKT3 or cyclosporine A as induction therapy. Am J Kidney Dis 1998, 32:575.
34. Pernambuco JR, Langley PG, Hughes RD. Fibrinolytic abnormalities following liver transplantation in patients with fulminant hepatic failure. Eur J Gastroenterol Hepatol 1995, 7:155.
35. Irish AB, Green FR. Environmental and genetic determinants of the hypercoaguable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997, 12:167.
36. Izumi S, Hughes RD, Langley PG. Acute phase response after liver transplantation for fulminant hepatic failure and cirrhosis. Transplant Int 1995, 8:340.
37. Kita Y, Iwaki Y, Demetris AJ, Starzl TE. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994, 57:1037.
38. Tilg H, Nordberg J, Vogel W. Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantation. Transplantation 1992, 54:142.
39. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13.
40. Mesters RM, Helterbrand J, Utterback BG. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000, 28:2209.
41. Bernard GR, Vincent JL, Laterre PF. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699.